(NVST) Envista Holdings - Ratings and Ratios

Envista Holdings Corporation (NYSE: NVST) is a leading global dental products company that designs, manufactures, and markets a wide range of innovative dental solutions. Headquartered in Brea, California, the company was established in 2018 and operates in over 40 countries worldwide, including the United States, China, and other international markets. Envistas product portfolio spans two primary segments: Specialty Products & Technologies and Equipment & Consumables. The company serves various dental professionals, including oral surgeons, prosthodontists, periodontists, orthodontists, and general dentists, as well as dental laboratories, clinics, and hospitals.

The Specialty Products & Technologies segment focuses on advanced dental solutions, including implant systems, guided surgery systems, and biomaterials. It also offers orthodontic products such as brackets, wires, clear aligners, and retainers. This segment is complemented by a suite of digital solutions, including the DTX Studio software platform, which supports implant planning, lab workflows, and clinical applications. Products in this segment are marketed under well-known brands like Nobel Biocare, Implant Direct, Damon, and Ormco.

The Equipment & Consumables segment provides essential dental supplies and equipment, such as digital imaging systems, endodontic systems, restorative materials, and infection prevention products. This segment also includes visualization and magnification systems, impression materials, and bonding agents. Key brands in this segment include Kerr, Dexis, Metrex, and Sybron Endo, catering to the daily operational needs of dental offices and clinics.

From a technical perspective, NVST is currently trading at $15.96, below its 20-day and 50-day moving averages of $15.78 and $17.49, respectively, but above its 200-day moving average of $18.66. The stock exhibits moderate volatility with an ATR of 0.85 and an average 20-day volume of 3.12 million shares. This indicates potential short-term resistance near the 50-day SMA and support near the 200-day SMA.

Fundamentally, Envista has a market capitalization of $2.75 billion, with a forward P/E ratio of 15.65, indicating expectations for earnings growth. The P/B ratio of 0.94 suggests the stock is undervalued relative to its book value, while the P/S ratio of 1.10 reflects a reasonable valuation for its revenue generation. However, the negative return on equity (RoE) of -38.12% raises concerns about profitability and efficiency.

3-Month Forecast: Based on the technical and fundamental data, NVST is likely to face resistance near its 50-day SMA ($17.49) and may experience selling pressure if it fails to breach this level. Support is expected near the 200-day SMA ($18.66), though the stocks current price is below this level, suggesting potential volatility. The negative RoE could weigh on investor sentiment, but the reasonable forward P/E and P/B ratios may attract value investors. Expect a trading range between $14.50 and $18.00 over the next three months, with potential upside if the company demonstrates improved profitability.